復星醫藥(02196.HK):內地居民可前往香港接種復必泰二價疫苗
復星醫藥(02196.HK)(600196.SH)公布,其控股子公司復星實業(香港)收到《藥品/製品註冊證明書》,基於本次合作引進的mRNA新冠疫苗BNT162b2(復必泰BNT162b2)、原始株/Omicron變異株BA.4-5二價疫苗(復必泰二價疫苗)均獲正式註冊為香港藥品/製品(生物製品)。其中,復必泰BNT162b2獲註冊用於12歲及以上人群的基礎免疫接種、復必泰二價疫苗獲註冊用於12歲及以上人群的加強接種。
該等疫苗是次於香港獲正式註冊是依據香港法例第138章。是次註冊後,有接種意願的人士可憑當地醫生處方於位於香港的醫療機構或診所接種該等疫苗(使用範圍將不再限於當地政府接種計劃下的接種)。意味著內地居民可前往香港接種復必泰二價疫苗。
復星醫藥H股現報24.9元,跌1.97%,成交148.25萬股,涉資3,744.64萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.